Abstract
Background The Middle Eastern population is characterized by increased prevalence of various Mendelian disorders owing to increased rates of consanguinity. Especially in disease conditions which require chronic transfusion support, it becomes important to know the blood group characteristics of potential donors to increase the likelihood of transfusion success. As there prevails a gap in knowledge about the population specific overall blood antigen profiles, this study seeks to utilize next generation sequencing datasets to unravel the comprehensive landscape of clinically significant minor blood group alleles in the middle eastern population.
Methods This study utilizes the genetic variation data from a range of public datasets including the Greater Middle East Variome, the Qatar genome and exomes and the Iranome datasets to estimate the genotypic and phenotypic frequencies of blood group alleles in the Middle Easterners. The estimated frequencies were duly compared with major global populations to identify significant similarities or differences if any.
Results A total of 77 unique ISBT approved blood group alleles were found commonly in all datasets. 8 variants (rs8176058, rs1058396, rs565898944, rs28362692, rs2071699, rs34783571, rs60322991 and rs57467915) belonging to KELL, KIDD, COLTON, H, JUNIOR and LANGEREIS blood groups were found clinically significant with previously reported evidence on transfusion complications. 730 variants were found to span exonic or splicing regions out of which 70 were predicted to be potentially deleterious by at least four computational tools.
Conclusions This study serves first of its kind to extensively characterize the known and novel blood alleles in the Middle Easterners. A comprehensive user-friendly online resource named alnasab - Alleles and antigens in Arab and Persian populations associated with blood groups was also developed as a dependable reference for future transfusion research. The resource is accessible at https://clingen.igib.res.in/alnasab/
Key points
Large scale Middle Eastern population sequencing datasets including The Greater Middle Eastern Variome, Genomes and exomes from Qatar and the Iranome datasets were used in the study.
A total of 2828 exomes and 88 genomes were analyzed accounting for a total of
18717 unique human blood group related variants.
2443 exonic variants were extracted which systematically included 1505 non-synonymous variants, 766 synonymous variants, 50 stopgain variants and 3 stop loss variants.
Blood group associated variants identified in the study are provided as a comprehensive online repository - alnasab, Alleles and antigens in Arab and Persian populations associated with blood groups. The resource is accessible at https://clingen.igib.res.in/alnasab/
Visual abstract
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Iranome - http://www.iranome.ir/Greater Middle Eastern Variome - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019950/ Qatar genomes and exomes - https://www.nature.com/articles/hgv201616#:~:text=After%20exclusion%20of%20first%20degree,n%3D853%20Exome51%20Mb).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
